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Background: The Global Influenza Hospital Surveillance Network (GIHSN) was developed to improve understanding
of severe influenza infection, as represented by hospitalized cases. The GIHSN is composed of coordinating sites,
mainly affiliated with health authorities, each of which supervises and compiles data from one to seven hospitals.
This report describes the distribution of influenza viruses A(H1N1), A(H3N2), B/Victoria, and B/Yamagata resulting in
hospitalization during 2012–2013, the network’s first year.
Methods: In 2012–2013, the GIHSN included 21 hospitals (five in Spain, five in France, four in the Russian
Federation, and seven in Turkey). All hospitals used a reference protocol and core questionnaire to collect data,
and data were consolidated at five coordinating sites. Influenza infection was confirmed by reverse-transcription
polymerase chain reaction. Hospitalized patients admitted within 7 days of onset of influenza-like illness were
included in the analysis.
Results: Of 5034 patients included with polymerase chain reaction results, 1545 (30.7%) were positive for influenza.
Influenza A(H1N1), A(H3N2), and both B lineages co-circulated, although distributions varied greatly between coordinating
sites and over time. All age groups were affected. A(H1N1) was the most common influenza strain isolated among
hospitalized adults 18–64 years of age at four of five coordinating sites, whereas A(H3N2) and B viruses were isolated
more often than A(H1N1) in adults ≥65 years of age at all five coordinating sites. A total of 16 deaths and 20 intensive
care unit admissions were recorded among patients with influenza.
Conclusions: Influenza strains resulting in hospitalization varied greatly between coordinating sites and over time.
These first-year results of the GIHSN are relevant, useful, and timely. Due to its broad regional representativeness and
sustainable framework, this growing network should contribute substantially to understanding the epidemiology of
influenza, particularly for more severe disease.
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According to the World Health Organization (WHO),
seasonal influenza epidemics affect an estimated 5–15% of
the total population worldwide, with 3–5 million cases of
severe illness, resulting in 250,000–500,000 deaths [1].
However, few data are available for many parts of the
world where active surveillance is lacking. In addition, the
viruses and the severity of influenza epidemics vary greatly
between years and geographical areas [2-4]. To address
the rapidly evolving antigenicity of circulating influenza vi-
ruses, twice annually, the WHO re-evaluates the viruses
that should be included in the seasonal influenza vaccines.
To inform policy decisions, national health authorities need
to understand the burden of influenza disease and the im-
pact of current vaccination programs in their countries.
High-quality, active surveillance networks are needed
to better understand influenza epidemiology and there-
fore better control influenza epidemics [5-7]. Data from
existing sentinel physician networks are used in several
countries to conduct annual studies on the effectiveness
of vaccines in preventing medically attended influenza-
like illness (ILI) [8-12]. These networks, however, do not
collect data on the impact of influenza infection on
hospitalization or on the impact of influenza vaccines on
influenza-related hospitalization, which substantially in-
fluence evaluation of the benefits and cost-effectiveness
of influenza vaccines [13].
Active surveillance networks are also powerful advocacy
instruments for highlighting the often-underestimated im-
pact of influenza [5]. While hospital surveillance systems
already exist for detecting outbreaks of respiratory viruses
[14-16], few focus on the actual burden of serious in-
fluenza cases using the specific outcome of laboratory-
confirmed influenza; instead, the burden is most often
estimated from hospital databases using criteria prone to
various biases [13,17].
The Global Influenza Hospital Surveillance Network
(GIHSN) was initiated in 2011 to fill this gap in epi-
demiology and public health knowledge. The GIHSN is
a public-private partnership between Sanofi Pasteur,
FISABIO-Salud Pública, and several coordinating sites
affiliated with national health authorities. In accordance
with WHO recommendations [7], coordinating sites are
selected based on their motivation, geographic repre-
sentativeness, ability to conduct epidemiological studies,
availability of laboratory facilities, and experience in in-
fluenza surveillance. Each coordinating site supervises a
group of one to seven hospitals in its country or geo-
graphical region and follows a core reference protocol.
The GIHSN has three main objectives: (i) evaluate the
burden of severe influenza disease, defined as hospita-
lization related to community-acquired influenza or com-
plications following an influenza infection; (ii) quantify the
distribution of the different influenza viruses (A(H1N1), A(H3N2), B/Yamagata, and B/Victoria) among these severe
cases; and (iii) measure the effectiveness of influenza sea-
sonal vaccines to prevent these hospitalizations using a
test-negative design.
In this report, we evaluated the characteristics of hos-
pitalizations related to influenza and the temporal and
geographic distribution of the different influenza viruses
in these cases during the 2012–2013 Northern hemi-
sphere influenza season, the program’s first year.
Methods
Study design
This was a multi-centre, prospective, active surveillance,
hospital-based epidemiological study during the 2012–
2013 influenza season in 21 hospitals in Spain, France,
Turkey, and the Russian Federation (Table 1). Data on
hospitalized patients with a diagnosis possibly associated
with influenza were collected by an active surveillance
system composed of healthcare professionals trained to
follow a common reference protocol. Data were consoli-
dated at five coordinating sites, including one in Spain
(Valencia), one in France, one in Turkey, and two in the
Russian Federation (Moscow and St. Petersburg).
The reference protocol was adapted by the coordinat-
ing sites according to their local conditions. In particular,
case identification was adapted to the specific local set-
ting because of the differences in health care delivery
systems between the different countries and differences
in the types of hospitals included, although admission
diagnosis codes for inclusion were the same for all sites.
At each site, except Turkey, the study start was prede-
fined according to the site experience of the influenza
epidemic wave [8]. No study period was defined for
Turkey because it was included as a pilot study. Specific-
ities between coordinating sites in the application of the
reference protocol are summarized in Table 2.
The GISHN study was approved by the local research
ethics committees for each institution: Comité Ético de la
Dirección General de Salud Pública y Centro Superior de
Investigación en Salud Pública (CEIC-DGSP-CSISP), Spain;
Comité de Protection des Personnes Ile-de-France III,
France; Ethic Committee of Hospital #1 for Infectious
Diseases of Moscow Health Department, the Russian
Federation; Ethics Committee of the Research Institute
of Influenza, St. Petersburg, the Russian Federation;
Istanbul University, Istanbul Faculty of Medicine, Ethical
Committee for Clinical Research, Turkey. All subjects in-
cluded in the study or their legal representatives provided
written informed consent following local research ethics
boards’ requirements.
Study population
Non-institutionalized patients hospitalized for at least
24 h with a diagnosis possibly associated with influenza
Table 1 Hospital characteristics
Country Participating
hospital
Type of Hospital Total no.
of beds
No. of beds for
general medicine
No. of beds for
paediatrics





General CS General 580 437 79 0 58
La Plana General 251 100 19 0 9
Pesset General 540 211 41 0 16
San Juan General 350 230 37 0 13
Elda General 514 410 30 0 13
France
Cochin - 1074 - - - -
Bichat University hospital 1000 954 0 20 24
Limoges - 858 - - - -
Montpellier - 3000 - - - -
Lyon University hospital/
tertiary care
683 603 0 64 53
Moscow
Hospital #1 Infectious diseases 1000 506 231 0 12
St.
Petersburg
Hospital #30 Infectious diseases 1200 1175 0 - 25
Hospital #5 Children's infectious
diseases
650 0 635 0 15
Hospital #4 Children's city hospital 360 0 345 0 15
Turkey
Hacettepe Univ. Hospital - 1200 156 228 - 60
Gazi Univ. Hospital - 1150 - - - -
Trakya Univ. Hospital University hospital 1042 951 72 0 50
Istanbul Univ. Cerrahpaşa
Hospital
University hospital - 36 60 0 30
Uludağ Univ. Hospital - 1000 800 112 0 87
Dr. Siyami Ersek Hospital - - - - - -
Kartal Research Hospital Research and education
Hospital
880 750 90 0 41
Dashes indicate missing information. No., number. ICU, intensive care unit.
Puig-Barberà et al. BMC Public Health 2014, 14:564 Page 3 of 12
http://www.biomedcentral.com/1471-2458/14/564were considered eligible to be included in the study (see
Additional file 1: Table S1 for admission diagnosis
codes). Patients in the Russian Federation, Spain, and
Turkey could be of any age, whereas in France, only pa-
tients ≥18 years of age were screened.
Subjects ≥5 years of age had to meet the European
Centre for Disease Prevention and Control’s clinical case
definition of influenza-like-illness (ILI) [18], which in-
cluded at least one of four systemic symptoms (fever or
feverishness, headache, myalgia, or malaise) and at least
one of three respiratory symptoms (cough, sore throat
or shortness of breath), although we did not include sud-
den onset of symptoms as a criterion. Subjects ≥5 years of
age also had to have been hospitalized within 7 days of the
onset of ILI. Children <5 years of age had to have been ad-
mitted to the hospital within 7 days of the appearance ofsymptoms potentially associated with influenza. Patients
were excluded if they had been discharged from a hospital
within 30 days of the current admission.
Data and sample collection
A nasopharyngeal swab was obtained from all pa-
tients. An additional pharyngeal swab was collected
for patients ≥14 years of age and a nasal sample for chil-
dren <14 years old. Samples were collected within 48 h of
hospital admission and were stored at −20°C at the study
site or were sent directly to the coordinating site’s labora-
tory for testing. Influenza infection status, patient demo-
graphics, and influenza vaccination status were recorded
with a core questionnaire via a combination of face-to-face
interview of patients or legal representatives, interviews of
attending physicians, and a review of clinical records.
Table 2 Protocol specificities between coordinating sites
Characteristic Valencia, Spain St. Petersburg, Russia Moscow, Russia Turkey France
Hospitals 5 health care district general
hospitals
1 infectious disease hospital, 1 children’s city
hospital, 1 children’s infectious disease hospital
1 infectious disease hospital 7 general hospitals 5 university hospitals




Screening diagnosis Admission diagnosis associated
with influenza infection; clinical
symptoms of ILI







illness for <7 days




Outside catchment area - - - Not affiliated with social
security
Study start criteria 2 consecutive weeks
with ≥2 cases
Week with ≥5 laboratory-confirmed influenza cases
using national surveillance data
Week with ≥5 laboratory-confirmed
influenza cases using national
surveillance data
Not defineda Defined by the national
surveillance system
Study end criteria 2 consecutive weeks
with no cases
Week with no laboratory-confirmed influenza cases Week with no laboratory-confirmed
influenza cases




2013-01 – 2013-15 2013-03 – 2013-22 2013-02 – 2013-21 2013-01 – 2013-14 2012-51 – 2013-16
aStudy period not defined because it was a pilot study. Cases of ILI were reported between epidemiological weeks 1 and 14 of 2013.
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collected with the core questionnaire was validated by exist-
ing registers or vaccination cards or by contacting the place
where patients were administered the vaccine. A patient
was considered as having received the current season’s in-
fluenza vaccination if their records demonstrated or if they
recalled receiving it >14 days before the onset of ILI.
Confirmation of influenza infection
RNA extraction and multiplex reverse transcriptase-
polymerase chain reaction (RT-PCR) were performed at
the coordinating sites to detect influenza A (H3N2), A
(H1N1)pdm09, B/Yamagata, and B/Victoria according to
local laboratory procedures. Coordinating sites in France,
the Russian Federation, and Turkey are WHO National
Influenza Centres, and the coordinating site in Valencia,
Spain used the WHO RT-PCR protocol. Details of the RT-
PCR methods are provided in the Additional file 2: Sup-
plemental methods.
Data management and statistical analysis
Coordinating sites collected anonymized data from the
core questionnaires and checked for missing, inconsist-
ent, or incorrect data. Whenever possible, queries of any
inconsistencies or missing data were resolved by the in-
vestigators at each of the coordinating sites. Missing data
were not replaced for the statistical analyses. Data from
each coordinating site were shared with the network coor-
dinating centre (FISABIO-Salud Pública, Valencia, Spain)





Records received, n 5038
Institutionalized, n 329
Non-resident a, n 63
Eligible, n 4646
Unable to communicate with patient or proxy, n 250
Consent not given, n 156
Screened for inclusion, n 4240
Did not meet inclusion/exclusion criteria, n 1872
Swab not taken, n 5
Eligible and tested, n 2363
RT-PCR results missing or invalid, n 67
Samples processed with RT-PCR results, n 2296
Sample taken outside the defined influenza season, n 789
Samples with valid RT-PCR results, n 1507
Influenza-positive, n (%) 236 (15.7)
Dashes indicate category not applicable.
aSpain only.Only samples taken within 7 days of symptom onset
were included in the analysis. Descriptive statistics were
calculated for the characteristics of influenza-associated
hospitalization by age group, influenza virus and socio-
demographic characteristics.
Statistical analysis and data management was performed
using STATA version 12 (StataCorp, College Station, TX).
Results
A total of 8795 patients hospitalized for diagnoses possibly
related to influenza were considered eligible for this study
(Table 3). Informed consent was obtained from 8162
(92.8%), who were subsequently screened for inclusion. A
total of 5034 patients with valid RT-PCR results were
included and, of these, 1545 (30.7%) were positive for in-
fluenza. Overall, the largest contributors of influenza-
positive samples were St. Petersburg (n = 652; 42.2%) and
Moscow (n = 471; 30.5%), followed by Spain (n = 236;
15.3%) and France (n = 150; 9.7%). Turkey, included as a
pilot study, accounted for 2.3% (n = 36) of the laboratory-
confirmed influenza cases. Hospitalization with confirmed
influenza was recorded for 15.7% of the included subjects
for Spain, 33.8% for Moscow, 39.6% for St. Petersburg,
34.7% for France, and 65.5% for Turkey.
Epidemiology of hospitalization with laboratory-
confirmed influenza
Cases hospitalized with confirmed influenza peaked be-
tween the fourth and eighth epidemiological week of






1986 1677 67 447 9215
7 21 0 0 357
- - - - 63
1979 1656 67 447 8795
47 2 1 0 300
166 11 0 0 333
1766 1643 66 447 8162
106 128 11 12 2129
7 115 0 0 127
1653 1400 55 435 5906
2 8 0 2 79
1651 1392 55 433 5827
3 0 0 1 793
1648 1392 55 432 5034
652 (39.6) 471 (33.8) 36 (65.5) 150 (34.7) 1545 (30.7)
Figure 1 Hospitalized influenza-positive and -negative cases by epidemiological week. Shown are the number of ILI cases with valid
RT-PCR samples and positive (laboratory-confirmed influenza; filled bars) or negative (open bars) for influenza virus.
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Spain, where the number remained elevated for the dur-
ation of the study because of the boarder criteria for case
identification. For all countries, the influenza season, as
defined by the appearance of confirmed influenza cases,
started around the beginning of 2013 (epidemiological
week 51 of 2012 to week 3 of 2013) and lasted until epi-
demiological week 14 to 22 of 2013. The influenza sea-
son was similar in Moscow and St. Petersburg, although
in St. Petersburg, influenza cases remained elevated over
a longer period with no clear peak. In Spain and France,
reporting of influenza cases began and ended earlier.All four influenza viruses examined in this study (A
(H1N1), A(H3N2), B/Yamagata, and B/Victoria) contrib-
uted to hospitalization with influenza at all five coordin-
ating sites. The timing and distribution of viruses varied
considerably between the coordinating sites (Figure 2).
In Moscow, A(H1N1) was the most frequent cause of
confirmed influenza (53.7% of cases), peaking at epi-
demiological week 5 of 2013, followed by an increase in
B and A(H3N2) towards the end of the season. A(H1N1)
was the most frequent cause of confirmed influenza in
Turkey, although results for the full season were not
available. In St. Petersburg, A(H1N1) was a frequent
Figure 2 Admissions with influenza by virus and epidemiological week.
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was also common and B lineages (37.9% overall) appeared
later. In Spain, B/Yamagata was the most frequent (60.6%
overall) and peaked around epidemiological week 6 of
2013, A(H1N1) increased later in the season. In France,
the frequency of B virus (44.0% overall) was slightly higher
than of the other influenza viruses, although it co-
circulated with the influenza A viruses. Both B virus
lineages circulated in all countries. The lineage in-
cluded in the vaccine (B/Yamagata) was most common,
representing 89.2% (436/489) of all B viruses cases in
which the lineage was identified.
At all coordinating sites except for France, A(H1N1)
was the most common influenza strain isolated fromhospitalized adults 18–64 years of age. In contrast, A
(H3N2) and B viruses were more common than A
(H1N1) in elderly adults (≥65 years of age) at all coord-
inating sites (Table 4).
Demographics and clinical features of hospitalized
laboratory-confirmed influenza cases
In Spain, France, and Turkey, more than half of influ-
enza cases had one or more comorbidities, whereas at
both coordinating sites in the Russian Federation,
more than 80% were reported to have no comorbidities
(Table 5). Cardiovascular disease, respiratory disease,
and diabetes were the most frequent comorbidities at
all coordinating sites among positives for influenza.
Table 4 Influenza cases detected by coordinating site, virus, and age group
Valencia (N = 236) St. Petersburg (N = 652) Moscow (N = 471) Turkey (N = 36) France (N = 150)
Virus < 18 y 18-64 y ≥ 65 y < 18 y 18-64 y ≥65 y < 18 y 18-64 y ≥ 65 y < 18 y 18-64 y ≥ 65 y 18-64 y ≥ 65 y
Total A 20 (40.0) 29 (54.7) 40 (30.1) 240 (64.0) 171 (66.0) 11 (61.1) 51 (64.6) 284 (75.9) 10 (55.6) 9 (100.0) 17 (94.4) 9 (100.0) 43 (64.2) 43 (51.8)
A(H1N1) 19 (38.0) 28 (52.8) 35 (26.3) 113 (30.1) 100 (38.6) 5 (27.8) 30 (38.0) 217 (58.0) 6 (33.3) 9 (100.0) 16 (88.9) 7 (77.8) 20 (29.9) 10 (12.0)
A(H3N2) 0 (0.0) 1 (1.9) 4 (3.0) 78 (20.8) 48 (18.5) 6 (33.3) 18 (22.8) 53 (14.2) 4 (22.2) 0 (0.0) 1 (5.6) 2 (22.2) 18 (26.9) 29 (34.9)
A - Not subtyped 1 (2.0) 0 (0.0) 1 (0.8) 49 (13.1) 23 (8.8) 0 (0.0) 3 (3.8) 14 (3.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (7.5) 4 (4.8)
Total B 30 (60.0) 24 (45.3) 93 (69.9) 144 (38.4) 96 (37.1) 7 (38.9) 28 (35.4) 91 (24.3) 8 (44.4) 0 (0.0) 1 (5.6) 0 (0.0) 26 (38.8) 40 (48.2)
B/Yamagata 28 (56.0) 23 (43.4) 92 (69.2) 127 (33.9) 80 (30.9) 6 (33.3) 6 (7.6) 12 (3.2) 2 (11.1) 0 (0.0) 1 (5.6) 0 (0.0) 20 (29.9) 39 (47.0)
B/Victoria 2 (4.0) 1 (1.9) 1 (0.8) 10 (2.7) 14 (5.4) 1 (5.6) 2 (2.5) 15 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (9.0) 1 (1.2)
B - Not subtyped 0 (0.0) 0 (0.0) 0 (0.0) 7 (1.9) 2 (0.8) 0 (0.0) 20 (25.3) 64 (17.1) 6 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total 50 (100) 53 (100) 133 (100) 375 (100) 259 (100) 18 (100) 79 (100) 374 (100) 18 (100) 9 (100) 18 (100) 9 (100) 67 (100) 83 (100)



















Table 5 Characteristics of subjects hospitalized with laboratory-confirmed influenza
Characteristic Valencia, Spain St. Petersburg, Russia Moscow, Russia Turkey France
Age N = 236 N = 652 N = 471 N = 36 N = 150
<18 y 50 (21.2) 375 (57.5) 79 (16.8) 9 (25.0) -
18 - 64 y 53 (22.5) 259 (39.7) 374 (79.4) 18 (50.0) 67 (44.7)
≥65 y 133 (56.4) 18 (2.8) 18 (3.8) 9 (25.0) 83 (55.3)
Sex N = 236 N = 652 N = 471 N = 36 N = 150
Male 124 (52.5) 347 (53.2) 151 (32.1) 22 (61.1) 69 (46.0)
Female 112 (47.5) 305 (46.8) 320 (67.9) 14 (38.9) 81 (54.0)
Pregnanta 1 (0.9) 1 (0.3) 242 (75.6) 1 (7.1) 4 (4.9)
Number of comorbidities N = 236 N = 652 N = 471 N = 36 N = 150
0 97 (41.1) 587 (90.0) 383 (81.3) 8 (22.2) 36 (24.0)
1 69 (29.2) 46 (7.1) 70 (14.9) 14 (38.9) 52 (34.7)
≥2 70 (29.7) 19 (2.9) 16 (3.4) 14 (38.9) 62 (41.3)
Chronic conditions N = 236 N = 652 N = 471 N = 36 N = 150
Cardiovascular disease 54 (22.9) 48 (7.4) 40 (8.5) 15 (41.7) 49 (32.7)
Respiratory disease 77 (32.7) 17 (2.6) 23 (4.9) 10 (27.8) 61 (40.7)
Diabetes 56 (23.7) 12 (1.8) 4 (0.9) 7 (19.4) 33 (22.2)
Immunodeficiency 7 (3.0) 0 (0.0) 0 (0.0) 7 (19.4) 14 (9.3)
Renal impairment 18 (7.6) 1 (0.2) 18 (3.8) 5 (13.9) 18 (12.0)
Rheumatologic disease 4 (1.7) 0 (0.0) 0 (0.0) 3 (8.3) 17 (11.3)
Neuromuscular disease 12 (5.1) 0 (0.0) 4 (0.9) 5 (13.9) 6 (4.0)
Cirrhosis 9 (3.8) 3 (0.5) 10 (2.1) 2 (5.6) 1 (0.7)
Neoplasm 5 (2.1) 4 (0.6) 6 (1.3) 8 (22.2) 18 (12.0)
Vaccinated 2012-2013 N = 236 N = 652 N = 471 N = 36 N = 150
Yes 82 (34.8) 11 (1.7) 6 (1.3) 5 (13.9) 50 (33.3)
No 154 (65.3) 641 (98.3) 465 (98.7) 31 (86.1) 100 (66.7)
Outcome N = 236 N = 652 N = 471 N = 36 N = 150
ICU admission 4 (1.7) 3 (0.5) 2 (0.4) 11 (30.6) -
Death 5 (2.1) 0 (0.0) 0 (0.0) 7 (19.4) 4 (2.7)
All values are number of subjects with percent in brackets. No data were missing. -, not reported.
aCalculated relative to females.
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influenza were ≥65 years of age, whereas <5% in St. Petersburg
and Moscow were in this age group. Most of the subjects
with influenza in Moscow were 18–64 years of age, while
in St. Petersburg, the only site including dedicated paedi-
atric hospitals, most were <18 years of age. The male-to-
female ratio for confirmed influenza cases was close to 1
in Spain, St. Petersburg, and France, whereas in Moscow,
more women than men were included. Indeed, a mater-
nity ward was included in this site, where 242 pregnant
women had influenza. Amongst women 15 to 45 years of
age hospitalized for diagnoses possibly related to influenza,
pregnancy was significantly associated with a risk of con-
firmed influenza (adjusted OR, 1.36 [95% CI, 1.03 – 1.80]).
A total of 16 deaths and 20 intensive care unit ad-
missions were recorded. Outcomes were similar at thedifferent coordinating sites, except for Turkey, which had
a disproportionately high number of serious outcomes (11
intensive care unit admissions and 7 deaths). For the 16
deaths, the mean age was 60 years (range, 1 – 93 years).
Nine of these patients were >65 years of age, two had been
vaccinated against seasonal influenza during the current
season, and seven had more than one comorbidity.
At all five coordinating sites, the length of hospital stay
was similar for all influenza circulating viruses (Additional
file 3: Figure S1).
Influenza vaccine uptake
Influenza vaccination coverage among all hospitalized pa-
tients included in the study, whether positive or negative
for influenza, was low in St. Petersburg (1.4%), Moscow
(1.7%), and Turkey (14.5%) and moderate in Spain (38.9%)
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tients was highest in elderly adults in Spain (60.7%),
Turkey (23.1%), and France (63.8%). In hospitalized chil-
dren, regardless RT-PCR results, uptake rates at all coord-
inating sites were very low (≤5%).
Discussion
These results represent the first year’s experience from
the GIHSN, a prospective hospital-based influenza sur-
veillance network. The data presented are from the
2012–2013 Northern hemisphere influenza season and
were collected from 21 hospitals via five coordinating
sites in four countries. Of a total of 6033 eligible pa-
tients, valid samples were obtained from 5034, of whom
1545 (30.7%) were positive for influenza.
The study confirmed that influenza can result in serious
outcomes not only in elderly people and those with comor-
bidities but also in the wider population, irrespective of age
or sex. It also confirmed that pregnant women are at sig-
nificant risk for hospitalization with influenza [19,20],
which supports global recommendations for prioritizing in-
fluenza vaccination for pregnant women [21,22].
The study allowed us to examine the influenza viruses
resulting in hospitalization. We found substantial hetero-
geneity in virus circulation between coordinating sites,
even those in neighbouring geographical areas and even
within the same site over time. Unexpectedly, influenza B,
mostly the Yamagata lineage, was the most common virus
identified in elderly adults, where it accounted for more
than half of the hospitalized confirmed influenza cases.
Thus, as found in a recent structured review [23], influ-
enza B poses a significant health burden. Indeed, influenza
B is now receiving increased attention, and quadrivalent
influenza vaccines containing both B lineages are now be-
coming available. Sample sizes were not large enough to
examine influenza viral strains according to comorbidities
and other risk factors including pregnancy, but this should
become possible as the GIHSN grows and sample sizes
increase.
Although the patients included in this study were not
necessarily representative of the overall population (i.e.
subset of hospitalized patients with a diagnosis possibly
associated with influenza), vaccination rates in these pa-
tients were lower than recommended by the WHO for
European countries [24]. The French patients in this
study, regardless their RT-PCR result, had the highest vac-
cination rate at 47.0%, which was similar to the overall
rate for France reported in 2010–2011 (50.4%) [25]. How-
ever, it is not unusual to observe some influenza cases in
vaccinated individuals because seasonal influenza vac-
cines have only a moderate protecting effect, especially
in elderly adults [26]. The lowest vaccination rates for
these patients were in the Russian Federation, where
fewer than 2% reported being vaccinated for seasonalinfluenza. This may have been due to the peculiarity of
the groups enrolled (e.g. mostly pregnant women in
Moscow and mostly children in St. Petersburg), poor up-
take, the ability of the vaccine to prevent hospitalization,
or a combination of these factors, although these influ-
ences remain to be assessed over the coming years.
The findings of this study are strengthened by the active
surveillance methodology, specific definitions at each site
of admission possibly related to an influenza infection, con-
firmation of influenza cases by RT-PCR, and the consistent
body of evidence generated across coordinating sites. In
addition, all RT-PCR was carried out by WHO National
Influenza Centres (France, Moscow, St. Petersburg, and
Turkey) or using the WHO protocol (Spain).
The results should be generally applicable because of
the diversity of participating hospitals and healthcare set-
tings. Nevertheless, the adaptation of case identification to
the specific local setting, mainly driven by practical con-
siderations, might have increased the sensitivity of the re-
sults to geographical variation. For future years, to help
reduce heterogeneity between sites, we plan a common
standard operating procedure and meetings at the begin-
ning of the study to share pilot data and harmonise criteria
and follow-up activities.
Conclusion
These first-year findings demonstrate that the GIHSN
produces relevant, important, and timely data. Despite
the size of the network, results were available before the
start of the following influenza season. These results will
help understand and prepare for seasonal influenza epi-
demics. In particular, this platform provides annual data
on the severe end of the influenza infection spectrum, as
represented by hospitalized cases, for a wide range of pop-
ulations. More formal burden and risk assessment will be-
come available as documentation of the catchment
population of these hospitals and wards improves. By
adding the ability to evaluate the impact of vaccination
programs, these data support those collected by SARI
surveillance systems, although the GIHSN employs a
broader definition of ILI that encompasses systemic
symptoms beyond fever (i.e., malaise, headache, and
myalgia).
The breadth of results provided by the GIHSN are par-
ticularly useful for assessing the effectiveness and cost-
effectiveness of intervention programs, and they open
the door to further research and public health activities,
especially on risk factors and the impact of influenza
and influenza vaccination programs in different popula-
tions. The approach used by the GIHSN also allows add-
itional components to be added to respond to other
scientific questions. During this first year of the GIHSN,
only 21 hospitals and four countries were included, but
additional hospitals and countries, including some from
Puig-Barberà et al. BMC Public Health 2014, 14:564 Page 11 of 12
http://www.biomedcentral.com/1471-2458/14/564the Southern hemisphere, have already agreed to join
the network. Thus, the GIHSN, with its broad regional
representativeness and sustainable framework, should
continue to contribute significantly to our knowledge of
influenza epidemiology.
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